It has been found that Hanmi Pharm recorded 216.5 billion won in outpatient prescription in South Korea in the first half of this year to top the list. Pfizer Pharmaceuticals Korea, which ranked first last year with 389.8 billion won, took the second place in the first half with 213.9 billion won.
In the domestic outpatient prescription market, Daewoong Pharmaceutical recorded the largest sales in 2013 and 2014 and Pfizer Pharmaceuticals Korea took the top spot in the following year while Hanmi Pharm ranked second or third for the three years. However, Hanmi Pharm succeeded in outperforming them this year with its Rosuzet for hypertension and hyperlipidemia patients, which was released last year, reaching 580 million won in sales in the second half of 2015, 3.2 billion won in the first quarter of this year and 5.3 billion won in the following quarter. In addition, its hypertension medicine Amosartan and reflux esophagitis medicine Esomezol totaled 33.3 billion won and 10.4 billion won in sales in the first half of this year, respectively.
In the meantime, new drugs manufactured by multinational pharmaceutical companies occupied top rankings in the sales amount. For example, Pfizer Pharmaceuticals Korea’s Lipitor for hyperlipidemia patients reached 76.5 billion won to take the top place and it is followed by Gilead Sciences Korea’s hepatitis B medicine Viread (72.4 billion won).
Hanmi Pharm’s Amosartan, ranking seventh, is the only entry on the top 10 list among the Korean pharmaceutical companies.